Literature DB >> 9617790

Platelet phenolsulphotransferase activity, monoamine oxidase activity and peripheral-type benzodiazepine binding in demented patients.

P Bongioanni1, M Donato, M Castagna, F Gemignani.   

Abstract

Blood platelet phenolsulphotransferase and monoamine oxidase activities, as well as platelet peripheral-type benzodiazepine binding have been studied in several neuropsychiatric disorders, in order to identify biochemical markers for altered brain functioning. In the present work, we determined platelet phenolsulphotransferase and monoamine oxidase activities in demented patients: they showed significantly higher phenolsulphotransferase and monoamine oxidase activities than controls. A significant positive correlation was found between enzyme activities and severity of illness. In the same subjects, we evaluated platelet peripheral-type benzodiazepine binding: a significant reduction of Bmax values was observed in demented patients, whereas Kd values did not substantially differ between the two subject groups. These findings are discussed with reference to central nervous system biochemical abnormalities of demented subjects: it may be that in Dementia of Alzheimer type either some central biochemical changes are reflected in certain peripheral tissues (such as platelets), or a systemic derangement occurs together with a cerebral involvement.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9617790     DOI: 10.1007/BF01276422

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  37 in total

1.  Family study of platelet membrane fluidity in Alzheimer's disease.

Authors:  G S Zubenko; M Wusylko; B M Cohen; F Boller; I Teply
Journal:  Science       Date:  1987-10-23       Impact factor: 47.728

2.  Radioenzymatic assay of sulfate conjugates of catecholamines and DOPA in plasma.

Authors:  G A Johnson; C A Baker; R T Smith
Journal:  Life Sci       Date:  1980-05-12       Impact factor: 5.037

3.  Distribution of free and conjugated dopamine in human caudate nucleus, hypothalamus, and kidney.

Authors:  M A Elchisak
Journal:  J Neurochem       Date:  1983-09       Impact factor: 5.372

4.  Platelet monamine oxidase in Alzheimer's disease.

Authors:  R C Smith; B T Ho; P Kralik; G Vroulis; J Gordon; J Wolff
Journal:  J Gerontol       Date:  1982-09

5.  Molecular biology of neurological and psychiatric disorders. I. Effect of parkinsonism, age, sex and L-dopa on platelet monoamine oxidase.

Authors:  E A Zeller; B Boshes; J Arbit; M Bieber; E R Blonsky; M Dolkart; S V Huprikar
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

6.  Benzodiazepine receptors on human blood platelets.

Authors:  P Moingeon; J J Dessaux; R Fellous; G F Alberici; J M Bidart; P Motté; C Bohuon
Journal:  Life Sci       Date:  1984-11-12       Impact factor: 5.037

7.  Human phenol sulfotransferase: correlation of brain and platelet activities.

Authors:  W F Young; E R Laws; F W Sharbrough; R M Weinshilboum
Journal:  J Neurochem       Date:  1985-04       Impact factor: 5.372

8.  Is the platelet phenolsulfotransferase involved in the sulfoconjugation of plasma catecholamines?

Authors:  Y Romain; S Demassieux; G D'Angelo; M Gyger; S Carrière
Journal:  Can J Physiol Pharmacol       Date:  1986-09       Impact factor: 2.273

9.  Peripheral type benzodiazepine binding sites are a sensitive indirect index of neuronal damage.

Authors:  J Benavides; D Fage; C Carter; B Scatton
Journal:  Brain Res       Date:  1987-09-22       Impact factor: 3.252

10.  The human platelet as a model for the glutamatergic neuron: platelet uptake of L-glutamate.

Authors:  R M Mangano; R Schwarcz
Journal:  J Neurochem       Date:  1981-03       Impact factor: 5.372

View more
  1 in total

1.  HNK-1 Carrier Glycoproteins Are Decreased in the Alzheimer's Disease Brain.

Authors:  María-Salud García-Ayllón; Arancha Botella-López; Inmaculada Cuchillo-Ibañez; Alberto Rábano; Niels Andreasen; Kaj Blennow; Jesús Ávila; Javier Sáez-Valero
Journal:  Mol Neurobiol       Date:  2016-01-06       Impact factor: 5.590

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.